Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Short term Debt (2020 - 2021)

PharmaCyte Biotech (PMCB) has disclosed Short term Debt for 7 consecutive years, with $66753.0 as the latest value for Q1 2021.

  • Quarterly Short term Debt changed N/A to $66753.0 in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $66753.0 through Jan 2021, changed N/A year-over-year, with the annual reading at $28918.0 for FY2020, N/A changed from the prior year.
  • Short term Debt for Q1 2021 was $66753.0 at PharmaCyte Biotech, up from $54110.0 in the prior quarter.
  • The five-year high for Short term Debt was $66753.0 in Q1 2021, with the low at $28918.0 in Q2 2020.